Expression of E- and
P-selectin ligands is required for T cell entry into skin.
Sialyl Lewis X moieties are critical for
ligand activity and are elevated on malignant skin-homing T cells. We hypothesize that these glycosylations are selectable targets for treating the dermal tropism associated with cutaneous
lymphomas. In this study, we analyzed the efficacy of a novel 4-fluorinated analog of
N-acetylglucosamine (GlcNAc) on E- and
P-selectin ligands expressed by malignant skin-homing T cells. We also examined the specificity of
4-F-GlcNAc (2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose) action by contrasting the effects on
sialyl Lewis X expression displayed by
P-selectin glycoprotein ligand-1 (PSGL-1) with sialylated O-
glycans expressed by CD43. Using parallel-plate flow analysis, we found that
4-F-GlcNAc elicited 5-fold more potent inhibition on
P-selectin ligand activity than on
E-selectin ligand activity. To determine whether glycosylations conferring E- and
P-selectin ligand activities were inhibited, we analyzed the expression of
sialyl Lewis X and sialyl-fucosylated core 2 O-
glycan (CHO-131 antigen), respectively. We found that
4-F-GlcNAc treatment resulted in dose-dependent ablation of
sialyl Lewis X and CHO-131
antigen expression on PSGL-1, whereas sialylated O-
glycans on CD43 were minimally affected. These results indicate that
4-F-GlcNAc treatment can selectively downregulate the
P-selectin ligand activity and potentially prevent dermal dissemination of cutaneous
lymphomas.